U.S. Software Stock News

Blue Bird stock has delivered a very strong 225.9% return over the past three years, yet the current market pricing lines up with a high overall value score while traditional earnings multiples still screen the shares as overvalued. That mix leaves investors weighing solid valuation checks against a richer headline multiple. Blue Bird's 225.9% return over three years highlights how much optimism has already been built into the share price. Expectations for sustained demand and cash...

Tower Semiconductor stock has delivered very strong gains over the past few years, yet the broad valuation checks currently point to a company that screens as expensive rather than a clear bargain. Over the past 5 years, Tower Semiconductor has returned about 7.9x, which means any new investor today is paying a price that already reflects a very strong run. Recent record revenue and profitability can support high expectations for future earnings, while any disappointment against those higher...

Apollo Global Management has delivered a 137.5% total return over the past five years, yet its current checks send a mixed valuation message, with an intrinsic value estimate based on the Excess Returns model pointing to upside while traditional earnings multiples lean the other way. A 137.5% gain over five years puts Apollo Global Management firmly in the group of stocks that have already rewarded long term holders, which can make fresh entries more sensitive to what happens next in...

Take-Two Interactive Software reported past first-quarter 2026 results with net revenue of US$1.53 billion, up modestly year on year, but recorded a net loss of US$34.1 million as impairment charges weighed on profitability while management reaffirmed guidance tied to the November launch of Grand Theft Auto VI. The company also issued new quarterly and updated full-year guidance, highlighting strong Grand Theft Auto VI pre-order momentum and resilient NBA 2K engagement even as mobile...

Class action lawsuits and legal investigations are now front and center for ADMA Biologics (ADMA), after several law firms alleged securities fraud related to related party transactions, channel stuffing, and disclosures about business practices. See our latest analysis for ADMA Biologics. At a latest share price of $9.90, ADMA Biologics has seen a 7 day share price return of 17.02% and a 90 day share price return of 21.18%, yet the year to date share price return is down 44.63%. Over the...

How the ACI Worldwide partnership reframes DLocal’s role in Latin American payments DLocal (DLO) stock is back in focus after ACI Worldwide agreed to plug the company’s local payments network into its orchestration platform for Brazil and Mexico, with more Latin American markets scheduled to follow. For investors, the partnership centers on a practical goal. ACI’s global merchants and fintech clients can use a single connection to access payment options like Pix, PicPay, Mercado Pago and...

Upcoming Q2 earnings and recent M&A focus attention on Quantum Computing Quantum Computing (NasdaqCM:QUBT) is back in focus as investors look ahead to its August 10 Q2 earnings presentation and react to recent M&A activity linked to the business. See our latest analysis for Quantum Computing. At a share price of $9.18, Quantum Computing has seen a 7 day share price return of 13.33% even though the year to date share price return is down 16.62%, while the 3 year total shareholder return is...

T-Mobile US recently launched new “Experience 2.0” and “Essentials 2.0” plans that add 36‑month Equipment Installment Plan options, including EIP Flex 36, allowing well-qualified customers to finance devices, taxes and fees with nothing due at checkout, alongside discounted Student Perks plans and 5G Home Internet bundles with prepaid card rebates of up to US$200. By shifting more customers toward longer-term device financing and targeted student offers, T-Mobile is reshaping how upfront...

Flowers Foods (FLO) has drawn investor attention after its share price closed at $7.40 on 4 September 2024, with the stock showing mixed shorter term returns and a weaker longer term profile. See our latest analysis for Flowers Foods. For context, the recent rebound in Flowers Foods, with a 1-day share price return of 2.21% and a 7-day share price return of 5.41%, comes after a much weaker backdrop. This includes a 30-day share price return down 11.59% and a 1-year total shareholder return...

In late July 2026, Repligen Corporation reported second-quarter 2026 results showing revenue rising to US$204.13 million while net income and earnings per share fell compared with a year earlier, and confirmed no share repurchases during the quarter under its existing buyback authorizations. The earnings release highlighted a contrast between growing top-line demand and pressure on profitability, offering fresh insight into how Repligen’s current cost structure and product mix are affecting...

Kilroy Realty’s late-July 2026 quarterly update showed lower second-quarter and year-to-date revenues and net income, while management reaffirmed full-year 2026 earnings guidance and detailed ongoing capital allocation moves, including completion of a US$72.62 million share repurchase and a US$66.997 million ESOP-related shelf registration for 1,700,000 shares. Alongside these results, executives highlighted a more active transaction landscape on the West Coast, with Kilroy carefully...

In early August 2026, Freshpet, Inc. reported second-quarter sales of US$305.59 million and net income of US$19.49 million, alongside meaningfully higher year-to-date profitability and earnings per share compared with the prior year. The company credited its strongest growth rate in over a year and highest adjusted gross margin since early 2020 to a mix shift toward loyal “MVP” households, rising buying rates, operational gains such as new bag technology, and reinforced this momentum by...

Niagen Bioscience (NAGE) has moved back into the spotlight after two recent developments. A peer reviewed analysis highlighted Niagen supplementation’s impact on muscle epigenetic age acceleration, while Tru Niagen’s launch on Walmart.com expands its healthy aging reach. See our latest analysis for Niagen Bioscience. Recent announcements around Niagen Bioscience, including the peer reviewed muscle aging study and Tru Niagen’s Walmart.com debut, come after a challenging share price stretch...

In early August 2026, Reinsurance Group of America reported second-quarter revenue of US$6,637 million and net income of US$462 million, both higher than a year earlier, alongside a 5.4% increase in its regular quarterly dividend to US$0.98 per share and continued execution of its share repurchase program. The combination of record operating results, stronger investment income, higher dividends, and ongoing buybacks highlights how RGA is using its balance sheet to enhance shareholder...

SPS Commerce, Inc. recently reported past second-quarter 2026 results, with sales rising to US$197.82 million while net income and diluted EPS from continuing operations fell to US$6.86 million and US$0.19, respectively, and also updated guidance calling for full-year 2026 revenue of US$788.4 million to US$793.4 million. Alongside these results, the company completed a US$113.64 million buyback equal to 4.93% of shares, signaling a meaningful capital return alongside expectations for revenue...

Tapestry (TPR) is back in focus after its second annual Future Now AI Summit, where the company highlighted how artificial intelligence is being used across consumer insights, store associate training, and enterprise decision intelligence. See our latest analysis for Tapestry. The Future Now AI Summit comes at a time of strong momentum in Tapestry’s stock, with a 30 day share price return of 15.86% and a 1 year total shareholder return of 50.75%. Over 3 years, the total shareholder return is...

In August 2026, Krystal Biotech reported second-quarter 2026 results showing net income of US$54.77 million, up from US$38.33 million a year earlier, with basic earnings per share from continuing operations rising to US$1.85 and diluted earnings per share to US$1.79. Over the first six months of 2026, net income reached US$110.70 million and basic earnings per share from continuing operations climbed to US$3.76, highlighting a meaningful increase in profitability compared with the prior-year...

RM-718 trial data puts Rhythm Pharmaceuticals (RYTM) pipeline in focus Rhythm Pharmaceuticals (RYTM) has drawn fresh investor attention after releasing preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, showing double digit mean BMI reductions and a generally well tolerated safety profile. See our latest analysis for Rhythm Pharmaceuticals. The RM-718 update has arrived alongside a sharp pickup in Rhythm Pharmaceuticals' share price momentum, with a 7-day share price return...

Why Avantor Raised Full Year Guidance After Q2 Results Avantor (AVTR) raised its full year guidance after returning to organic growth in its distribution business, with the VWR segment showing earlier than expected improvement and the Revival program delivering measurable operational progress. The updated outlook follows second quarter 2026 earnings, where Avantor reported sales of US$1,692.3 million and net income of US$38.1 million, alongside modestly higher first half sales and lower net...

Sea Limited has moved back into focus this week as investors react to recent trading volatility and look ahead to its 11 August 2026 earnings release, with consensus pointing to year-over-year gains in both earnings per share and revenue across e-commerce and digital entertainment. Behind the headlines, the key tension is between upbeat growth expectations and mounting concern that heavier spending and higher credit loss provisions could weigh on profitability. Next, we’ll examine how this...

Berkshire Hathaway has quietly flipped the script in Q2 2026, shifting from record cash reserves to heavier investing and buybacks, and that ripple is now reaching individual stocks. This change in behaviour can open up pockets of opportunity and pockets of risk for investors who pay attention. This article walks through three stocks exposed to the same forces, two potential beneficiaries and one possible loser, to help you decide where to lean in and where to be cautious. Allstate...

Altria Group (MO) moved back into focus after its late July Q2 2026 earnings release, which combined a revenue beat with an earnings miss and a tighter full year adjusted EPS outlook. See our latest analysis for Altria Group. The mixed Q2 2026 earnings picture and ongoing share buybacks appear to be key drivers behind Altria Group's recent moves, with the share price at US$68.35 after a 19.26% year to date share price return and a 5 year total shareholder return of 106.98%. This suggests...

Tilray Brands (TLRY) just rolled out Mollo Lite Blackberry Lemon Seltzers as its first light THC beverage multipack in Canada, putting fresh attention on how the stock reflects its cannabis beverage platform. See our latest analysis for Tilray Brands. The new Mollo Lite launch lands after a mixed run for Tilray Brands, with a 1-day share price return of 2.93% to US$4.57 and a 30-day share price return of 4.10%, but a year-to-date share price decline of 52.98% and a 5-year total shareholder...

Earnings and Guidance Update Put CONMED Stock in Focus CONMED (CNMD) drew fresh attention after reporting second quarter 2026 results, with net income and earnings per share higher than a year earlier and a modestly raised full year net sales outlook. See our latest analysis for CONMED. The latest earnings and modest guidance lift have come alongside a sharp shift in sentiment, with CONMED’s share price up 46.23% over the past month. However, the 1 year total shareholder return is still down...